Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 947-951

  Huang, Lizhen ^a   Huang, Jie ^a   Wu, Peng ^a   Li, Qian ^a   Rong, Liucheng ^a   Xue, Yao ^a   Lu, Qin ^a   Li, Jie ^b   Tong, Na ^a   Wang, Meilin ^a   Zhang, Zhengdong ^a   Fang, Yongjun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

acute lymphoblastic leukemia; Childhood; MTOR

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CELL SURVIVAL; CHILD; CHILDHOOD CANCER; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; INFANT; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK; TOR SERINE-THREONINE KINASES;

EID: 84859940689     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.628062     Document Type: Article

References (31)

1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277-285.
2. Howard SC, Metzger ML, Wilimas JA, et al. Childhood cancer epidemiology in low-income countries. Cancer 2008;112:461-472. (Pubitemid 351186186)
3. Nguyen K, Devidas M, Cheng SC, et al. Factors infl uencing survival after relapse from acute lymphoblastic leukemia: A Children's Oncology Group study. Leukemia 2008;22:2142-2150.
4. Eden T. Aetiology of childhood leukaemia. Cancer Treat Rev 2010;36:286-297.
5. Vijayakrishnan J, Houlston RS. Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: A systematic review and meta-Analysis. Haematologica 2010;95:1405-1414.
6. Karathanasis NV, Choumerianou DM, Kalmanti M. Gene polymorphisms in childhood ALL. Pediatr Blood Cancer 2009;52:318-323.
7. Yan J, Yin M, Dreyer ZE, et al. A meta-Analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children. Pediatr Blood Cancer 2011 Apr 14. [Epub ahead of print]
8. Dai L, Gast A, Horska A, et al. A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. Pediatr Blood Cancer 2009;52:819-823.
9. Guertin DA, Sabatini DM. Defi ning the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
10. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects. Cell Cycle 2009;8:403-413.
11. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009;122:3589-3594.
12. Carayol N, Vakana E, Sassano A, et al. Critical roles for mTORC2-And rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010;107:12469-12474.
13. Kelly KR, Rowe JH, Padmanabhan S, et al. Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol 2011;6:53-61.
14. Crazzolara R, Cisterne A, Th ien M, et al. Potentiating eff ects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 2009;113:3297-3306.
15. Slattery ML, Herrick JS, Lundgreen A, et al. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: MTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 2010;31:1604-1611.
16. Subspecialty Group of Hematology Diseases, The Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics. [Suggestion of diagnosis and treatment of acute lymphoblastic leukemia in childhood]. Zhonghua Er Ke Za Zhi 2006;44:392-395.
17. Xue Y, Xu H, Rong L, et al. The MIF -173G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk Res 2010;34:1282-1286.
18. Latino-Martel P, Chan DS, Druesne-Pecollo N, et al. Maternal alcohol consumption during pregnancy and risk of childhood leukemia: Systematic review and meta-Analysis. Cancer Epidemiol Biomarkers Prev 2010;19:1238-1260.
19. MacArthur AC, McBride ML, Spinelli JJ, et al. Risk of childhood leukemia associated with parental smoking and alcohol consumption prior to conception and during pregnancy: The cross-Canada childhood leukemia study. Cancer Causes Control 2008;19:283-295.
20. Bailey HD, Milne E, de Klerk NH, et al. Exposure to house painting and the use of fl oor treatments and the risk of childhood acute lymphoblastic leukemia. Int J Cancer 2011;128:2405-2414.
21. Lee KM, Ward MH, Han S, et al. Paternal smoking, genetic polymorphisms in CYP1A1 and childhood leukemia risk. Leuk Res 2009;33:250-258.
22. Murakami M, Ichisaka T, Maeda M, et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 2004;24:6710-6718. (Pubitemid 38944350)
23. Chiarini F, Grimaldi C, Ricci F, et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010;70:8097-8107.
24. Cardoso BA, Martins LR, Santos CI, et al. Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia 2009;23:206-208.
25. Bertrand FE, Spengemen JD, Shelton JG, et al. Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia 2005;19:98-102. (Pubitemid 40090083)
26. Chiarini F, Fala F, Tazzari PL, et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009;69:3520-3528.
27. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, et al. Cytotoxic eff ect of 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: Implication for targeted therapy. Mol Cancer 2007;6:46.
28. Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23:655-674.
29. van der Burg M, Poulsen TS, Hunger SP, et al. Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia 2004;18:895-908. (Pubitemid 38714612)
30. Hildebrandt MA, Yang H, Hung MC, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009;27:857-871.
31. Pu X, Hildebrandt MA, Lu C, et al. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 2011;71:82-88.